Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow. Read More
Korean bioventure Curacle Co. Ltd. reported positive top-line findings from its U.S.-based phase IIa study of CU06-1004, an oral drug for diabetic macular edema, spurring plans for a bigger phase IIb study in the second half of 2024. Read More
Celltrion Inc. has taken under its wing four Korean biotech startups as part of its joint “Open Innovation” program co-run with Seoul Biohub since October 2023, adding to its efforts to grow into a Korean biopharma giant with incubating prowess. Read More
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline. Read More
The biopharma industry started 2024 on the upswing, with all four categories of financings tracked by BioWorld up in value compared to last January, and also up from December. In comparison to January 2023, IPO value soared 262%, follow-ons surged by 247%, public/other offerings saw a 381% rise, and private financings experienced a 21% bump. Read More
Armed with strong phase III safety data in Japanese patients, Palo Alto, Calif.-based Bridgebio Pharma Inc. is planning to file for Japan approval of its investigational drug acoramidis for a rare heart disorder. Read More
Encoded Therapeutics Inc. is advancing its lead gene therapy candidate, ETX-101, for the treatment of SCN1A+ Dravet syndrome into the clinic. Read More
Researchers from Lanzhou University have described the discovery and preclinical evaluation of new multifunctional opioid agonists being developed as potential antinociceptive agents. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Astellas, Eli Lilly Glenmark, Hutchmed, Ichnos Sciences, Inmagene, Takeda, Zuellig. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astellas, Astrazeneca, Biontech SE, Biosyngen, Bristol Meyers, Celltrion, Daewoong, Gracell. Hutchmed, Junshi, Oricell, Takeda. Read More
